Online Meeting 4-7 June 2021

VARIAN Symposium

Saturday 5 June 1:00pm UTC / GMT

A live public stream of Varian’s symposium will be available here on Saturday 5 June 1:00pm UTC. Registered delegates are advised to watch within the Online Meeting Platform to access the full range of services.

Expanding Access to Proton Therapy Worldwide

Please join Varian, a Siemens Healthineers company, for a symposium on Expanding Access to Proton Therapy Worldwide. Hear from Dr. Charles Simone II from the New York Proton Center about how his center successfully implemented proton SBRT. Brendan Burgdorf from the University of Pennsylvania will discuss how his center has built and evaluated an AI-driven RapidPlan model for H&N oropharynx cases with bilateral nodal involvement. Varian will discuss our new combination with Siemens Healthineers, share highlights from our system installations in Asia, provide an overview of recent product innovations, and give an update on Varian’s patient-centered FLASH program. 

Symposium Program


Kolleen Kennedy - President, Proton Solutions & Growth Office

Expansion of Global ProBeam Installations

Brendan Lyden - Vice President, Global Site Solutions, VPS

Advancing Proton Therapy Through Innovation

Jan Timmer - Senior Director, PT Marketing

Advances in Proton SBRT with Pencil Beam Scanning

Charles B. Simone, II MD, FACRO - Chief Medical Officer, New York Proton Center

RapidPlan PT Modeling for H&N Oropharynx Cases

Brendan Burgdorf, MMP, DABR - Proton Medical Physicist, University of Pennsylvania

FLASH Program at Varian: Patient Centered Innovation

Agam Sharda - Vice President, FLASH Solutions



Kolleen T. Kennedy

Kolleen T. Kennedy was named president of Proton Solutions, the division formerly known as Particle Therapy, and Chief Growth Officer in October 2018. In this role, she is responsible for growing Varian Proton Solutions offerings as well as overseeing the Company’s Acquisition Integration Office, Strategic Program Management organization and Customer Experience initiatives. Prior to this appointment, Ms. Kennedy was Corporate Executive Vice President and President of Varian Oncology Systems (VOS) for seven years. Under her leadership, VOS total revenues grew by a 4 percent compounded annual growth rate, and she served as the key architect in transforming the organization into geographic structures—establishing a global footprint that enabled emerging markets revenue to grow by 15 percent. From 2005 to 2011, Ms. Kennedy served as Vice President and General Manager of the Customer Support Services (CSS) organization. Under her leadership, Varian’s CSS organization was rated the #1 service provider among linear accelerator manufacturers every year by IMV, Ltd., an independent healthcare market research firm that analyzes service trends. Ms. Kennedy joined Varian in 1997 as Marketing Manager for delivery systems. She was promoted to manage Oncology Systems marketing in 2001 and the engineering function in 2002. In 2006, Ms. Kennedy was selected by the YWCA of Santa Clara Valley, California, as one of that year’s “Tribute to Women and Industry” (TWIN) honorees for her outstanding achievements as a corporate executive. In 2017, she achieved the Silicon Valley Business Journal Women of Influence award, which honors women who are having a major impact as executives, entrepreneurs and community leaders. Prior to joining Varian, Ms. Kennedy was with Siemens Medical and Radiation Oncology Computer Systems in radiation oncology product sales and marketing. Currently, Ms. Kennedy serves on the Board of Directors for the Wayne State University Foundation, which encourages and manages financial support from private sources to provide the university’s students, faculty and scientists with learning and discovery opportunities. She also serves on the Union for International Cancer Control (UICC) World City Cancer Challenge Board, which aims to increase the number of people with access to quality cancer treatment in cities around the world. Ms. Kennedy holds a BS in radiation oncology and a BS in psychology from Wayne State University and an MS in medical physics from the University of Colorado Health Sciences Center.

Brendan Lyden

With more than 20 years of Proton Therapy System design, construction, installation and commissioning experience, Brendan Lyden leads Varian’s Global Site Solution’s Team. Brendan holds a BS in Physics from Southern Connecticut State University and an MBA from Jacksonville University. Prior to this Brendan was a member of the United States Navy, serving for 6 years aboard nuclear submarines as a member of the engineering team.

Jan Timmer

Jan Timmer is the Marketing Director for Varian Proton Solutions with twenty years of experience in the field of proton therapy. In this role he is responsible for portfolio management, commercialization and promotion of proton therapy products and services. Mr. Timmer was responsible for the launches of the ProBeam and ProBeam 360° platforms. Prior to joining Varian, he was with Accel Instruments GmbH in engineering and product management and part of the team that developed the first commercially available IMPT delivery system. Mr. Timmer holds a MS in applied physics from the University of Groningen and a MS in Financial Economics from the Erasmus University in Rotterdam. He and his family are living in California.

Charles B. Simone

Charles B. Simone, II, MD, FACRO is a Research Professor and the Chief Medical Officer of the New York Proton Center. He is also a Full Member in the Department of Radiation Oncology at Memorial Sloan Kettering Cancer Center. He is an internationally recognized expert in the use of proton therapy to treat thoracic malignancies and for reirradiation, and in the development of clinical trial strategies and innovative research in thoracic radiation oncology and stereotactic body radiation therapy. He is a National Institutes of Health, National Science Foundation, and Department of Defense funded investigator who performs clinical and translational research investigating the benefits of proton therapy as part of multi-modality therapy for lung cancer, malignant pleural mesothelioma, and other thoracic malignancies.

Prior to coming to the New York Proton Center, Dr. Simone was Chief of the Thoracic Oncology Service at the Hospital of the University of Pennsylvania, Director of the Penn Mesothelioma and Pleural Program, and Director of Clinical Research and Operations in the Department of Radiation Oncology at Penn. He was then appointed Medical Director of the Maryland Proton Treatment Center, and at the University of Maryland, he also served as Chair of the Clinical Research Committee for their Comprehensive Cancer Center, proton therapy Fellowship Director, and Director of the Stereotactic Radiation Therapy Program. He completed his undergraduate and medical school training at the University of Pennsylvania, internship in internal medicine, and residency training in radiation oncology at the National Cancer Institute, NIH, where he served as chief resident.

Dr. Simone has published >390 peer-reviewed scientific articles and book chapters, given >245 scientific lectures to national and international audiences, and is the national Principal Investigator or Co-Chair of 7 NIH-funded cooperative group trials (4 NRG Oncology, 1 SWOG, 1 ECOG-ACRIN, 1 PCG). He is a three-time winner of the Association of Residents in Radiation Oncology (ARRO) Educator of the Year Award, and he has been elected for Fellowship in the American College of Radiation Oncology (FACRO). Dr. Simone is the Proton Collaborative Group (PCG) President of the Board of Directors and Chairs or Co-Chairs the PCG Executive Committee; PCG Lung Committee; American Society for Radiation Oncology (ASTRO) Lung Resource Panel Committee; ASTRO Small Cell Lung Cancer Guidelines Committee; American Radium Society-American College of Radiology (ARS-ACR) Appropriate Use Criteria Thoracic Committee; Particle Therapy Co-Operative Group (PTCOG) Gastrointestinal Subcommittee; PTCOG Skull Base/Central Nervous System, Sarcoma Subcommittee; American College of Radiation Oncology (ACRO) Recruitment Subcommittee; ACRO Annual Meeting Abstracts Committee; and National Cancer Institute/Radiosurgery Society (RSS) GRID-Lattice-Microbeam-Flash Radiotherapy Clinical Working Group. He is the Editor-in-Chief of Annals of Palliative Medicine and on the Editorial Boards of Journal of Clinical Oncology, Cancers, Journal of Thoracic Disease, Frontiers in Oncology, Translational Lung Cancer Research, Annals of Translational Medicine, and Therapeutic Radiology and Oncology.

Brendan Burgdorf

Brendan Burgdorf, MMP, DABR is a clinical proton physicist at the University of Pennsylvania. He received his Master’s in Medical Physics and residency training at UPenn, as well. In addition to the general proton physics duties, he is the lead proton planning physicist. This responsibility involves planning clinical cases, updating procedures, and investigating new planning technologies. He also assists in teaching efforts in the residency and master’s programs.

Agam Sharda

Agam Sharda is the Vice-President of Varian’s Flash Solutions. Mr. Sharda has more than 15 years of experience in Radiation Therapy, Radiosurgery, and Cancer Diagnostics across a multitude of roles in Product Management, Marketing, and Business Leadership. He is passionate about creating and delivering innovation to fight against cancer and positively impact patients’ lives.

Conference Secretariat: C-IN, 5. kvetna 65, 140 21 Prague 4, CZE | tel.: +420 261 174 301 | fax: +420 261 174 307
Home | Sitemap | Copyrights and Trademarks | Privacy Policy | info@ptcog59.org | Copyright © 2019 ptcog59.org
Powered and created by E-WORKS - web studio | XHTML 1.0 | CSS 2

Conference Secretariat: C-IN, 5. kvetna 65, 140 21 Prague 4, CZE | tel.: +420 261 174 301 | fax: +420 261 174 307
Home | Sitemap | Copyrights and Trademarks | Privacy Policy | info@ptcog59.org | Copyright © 2019 ptcog59.org
Powered and created by E-WORKS - web studio | XHTML 1.0 | CSS 2